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A B S T R A C T
The development of tolerance to the antinociceptive effect is a main problem associated with the repeated
administration of opioids. The progressively higher doses required to relieve pain reduce safety and exacerbate
the side effects of classical opioid receptor agonists like morphine. Nociceptin/orphanin FQ (N/OFQ) and its
NOP receptor constitute the fourth endogenous opioid system that is involved in the control of broad spectrum of
biological functions, including pain transmission. Aim of this work was to evaluate the relevance of the N/OFQ-
NOP system in morphine antinociceptive action and in the development of morphine tolerance in the rat.
Continuous spinal intrathecal infusion of morphine (1–3 nmol/h) evoked analgesic effects for 5 days in wild type
animals. The same doses infused in NOP(-/-) rats showed a lower analgesic efficacy, while the onset of tolerance
was delayed to day 9. N/OFQ (1–3 nmol/h), continuously infused in NOP(+/+) animals, showed an analgesic
profile similar to morphine. Immunohistochemical analysis of the dorsal horn of the spinal cord of morphine
tolerant NOP(+/+) rats showed an increased number of Iba1- and GFAP-positive cells (microglia and astro-
cytes, respectively). Interestingly, microglia but not astrocyte activation was observed in NOP(-/-) morphine
tolerant rat. A selective activation of astrocytes was observed in the dorsal horn of wild type N/OFQ tolerant rats.
The antinociceptive effect of morphine partially depends by the N/OFQ-NOP system that participates in the
development of morphine tolerance. In particular, NOP receptors are involved in morphine-induced astrocyte
activation, and N/OFQ per se increases astrocyte density.
1. Introduction
Morphine is one of the most powerful drug used in pain relief and
remains a preferred and commonly prescribed analgesic for pain
management (Denlinger et al., 2014). Although it shows remarkable
efficacy for treating chronic pain conditions, there are several limita-
tions to its use (Yuill et al., 2016), including rapid development of
tolerance, which is characterized by a decrease in antinociceptive ef-
ficacy (Self and Nestler, 1995). To overcome tolerance and achieve
equivalent pain relief, the opioid dose is progressively escalated which
can exacerbate the unwanted effects (Thorn et al., 2016). Mechanisms
of tolerance are complex and involves changes in receptors, ion chan-
nels cell and neuronal networks functions (Ji, 2010; Johansson et al.,
2010; Zhang et al., 2015). According to a classical view these re-ar-
rangements occur at the neuronal level, however growing evidence
indicates a potential role of glia cells that are activated by repeated
administrations of morphine (Di Cesare Mannelli et al., 2015; Horvath
and DeLeo, 2009; Mika, 2008; Mika et al., 2009; Raghavendra et al.,
2002; Song and Zhao, 2001; Watkins et al., 2005). Morphine treatment
induces astrocyte and microglia changes resulting in increased pro-
duction of many soluble factors such as proinflammatory cytokines and
chemokines, neurotrophic factors, prostaglandins, nitric oxide, com-
plement proteins, free radicals, neurotoxins and excitatory amino acids
that counteract opioid analgesia (Eidson and Murphy, 2013; Hameed
et al., 2010). The pharmacological inhibition of microglia and astrocyte
with minocycline and fluorocitrate, respectively, attenuates the onset of
tolerance in rats (Cui et al., 2008; Song and Zhao, 2001).
Nociceptin/orphanin FQ (N/OFQ), a heptadecapeptide from the
opioid family, and its cognate NOP receptor (previously called the
opioid receptor-like, ORL1), are present in nociceptive pathways in
spinal cord and brain with a complex role (Schröder et al., 2014,
Zeilhofer and Calò, 2003). N/OFQ differentially modulates nociception
depending upon site of administration, dose, assay, and animal species.
N/OFQ injected intracerebroventricularly (i.c.v) decreases the pain
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threshold in the hot-plate and tail-flick assays (Meunier et al., 1995;
Reinscheid et al., 1995). Moreover, after the i.c.v. administration, N/
OFQ attenuates morphine analgesia (Mogil et al., 1996). On the con-
trary, intrathecal (i.t.) administration of the peptide shows acute anti-
nociceptive activity in the tail-flick and in the paw pressure tests
(Micheli et al., 2015a; Xu et al., 1996). Similarly, in models of neuro-
pathic and inflammatory pain, i.t. injections of N/OFQ have also been
shown to produce anti-hyperalgesic (Micheli et al., 2015b) and anti-
allodynic effects and to potentiate morphine anti-hyperalgesia
(Courteix et al., 2004; Hao et al., 1998; Yamamoto et al., 1997). Despite
these studies prove the properties of N/OFQ to evoke antinociceptive
effect after spinal administration, no definitive data are reported re-
garding the involvement of the NOP system in the onset of opioid an-
algesic morphine tolerance.
Aiming to evaluate the involvement of the NOP system in the onset
of morphine tolerance, morphine was administered in NOP(+/+) and
NOP(-/-) animals through an intrathecal catheter that allowed a con-
tinuous infusion of the compounds at the lumbar level of the spinal
cord. The glial activation profile was studied in the dorsal horn in
comparison to the same treatment with N/OFQ.
2. Materials and methods
2.1. Animals
Male Sprague-Dawley and Wistar rats were supplied by Envigo
(Varese, Italy). Male NOP(-/-) rats, supplied by GenOway (Lyon,
France), were generated in a Brown Norway background and subse-
quently backcrossed on a Wistar background for four generations as
previously described in detail (Homberg et al., 2009). For knockout
studies Wistar rats were used as controls and indicated as NOP(+/+).
Animals, weighing approximately 280–300 g at the beginning of the
experimental procedure, were housed in Ce.S.A.L (Centro Stabulazione
Animali da Laboratorio, University of Florence) and used at least one
week after their arrival. Four rats were housed per cage (size 26 ×
41 cm) kept at 23± 1 °C with a 12 h light/dark cycle, light at 7 a.m.;
animals were fed with standard laboratory diet and tap water ad libitum.
All animal manipulations were carried out according to the Directive
2010/63/EU of the European parliament and of the European Union
council (22 September 2010) on the protection of animals used for
scientific purposes. The ethical policy of the University of Florence
complies with the Guide for the Care and Use of Laboratory Animals of
the US National Institutes of Health (NIH Publication No. 85-23, revised
1996; University of Florence assurance number: A5278-01). Formal
approval to conduct the experiments described was obtained from the
Animal Subjects Review Board of the University of Florence. Experi-
ments involving animals have been reported according to ARRIVE
guidelines (McGrath and Lilley, 2015). All efforts were made to mini-
mize animal suffering and to reduce the number of animals used.
2.2. Intrathecal catheterization
Rats were anesthetized with 2% isoflurane and intrathecal catheter
was surgically implanted according to the Yaksh and Rudy (1976)
method. Rats were shaved on the back of the neck and placed in the
stereotaxic frame with the head securely held between ear bars. The
skin over the nap of the neck was cleaned with ethyl alcohol and incised
for 1 cm. The muscle on either side of the external occipital crest was
detached and retracted to expose about 3–4mm2 of the atlanto-occi-
pital membrane. The membrane was incised by a needle, which led to
the escape of cerebrospinal fluid. The caudal edge of the cut was lifted
and about 7.0 cm of 28G polyurethane catheter (0.36mm outer dia-
meter; 0.18mm inner diameter; Alzet, USA) was gently inserted into
the intrathecal space in the midline, dorsal to the spinal cord until the
lumbar enlargement. The exit end of the catheter was connected to the
osmotic pumps (Alzet, USA) for continuous infusion. Then pumps were
subcutaneously fixed on the back of the head. The incision site in the
skin was sutured with polyamide wire and animals were allowed to
recover for 24 h before the study began.
All animals used during behavioral tests did not shown motor im-
pairment induced by surgical operation for the catheter implantation.
The evaluation of potential motor dysfunctions were investigated using
the Rota rod test (Ugo Basile, Varese, Italy). The animals that re-
presented any kind of motor disability (approximately 15%) were ex-
cluded from the behavioral measurements.
2.3. Drug intrathecal treatments
Morphine hydrochloride was from S.A.L.A.R.S., Como, Italy. N/OFQ
was synthesized and purified as previously described in details (Arduin
et al., 2007; Guerrini et al., 1997). All compounds were dissolved in
sterile saline solution.
For continuous infusion, compound concentrations were adjusted to
release 1 and 3 nmol/h morphine or N/OFQ from a mini-osmotic pump
ALZET 1002 (USA) with a flow rate 0.25 µL/h. Final solutions were
filtered by a 0.22 µm pore size Hydrophilic PVDF membrane (Millipore,
Italy). Mini-pumps were attached to the described polyurethane
Fig. 1. Analgesic effect induced by continuous intrathecal infusion of morphine in NOP
(+/+) and in NOP(-/-) rats. a) The opioid compound was dissolved in sterile saline
solution and infused in two different groups of animals both at the dose of 1 nmol/h with
osmotic pumps until day 10. Vehicle NOP(+/+) and vehicle NOP(-/-) groups were in-
fused with sterile saline solution. The nociceptive threshold was evaluated every day by
Paw pressure test, starting on the 1st day of treatment. b) The opioid compound was
dissolved in sterile saline solution and infused in two different groups of animals, both at
the dose of 3 nmol/h with osmotic pumps until day 10. Vehicle NOP(+/+) and vehicle
NOP(-/-) groups were infused with sterile saline solution. The nociceptive threshold was
evaluated every day by Paw pressure test, starting on the 1st day of treatment. Each value
represents the mean of 8 rats performed in 2 different experimental sets. Data are shown
as mean± S.E.M; ^^P< 0.01 vs vehicle NOP(+/+) infused rats; **P< 0.01 vs vehicle
NOP (-/-) infused rats.
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catheters and filled with compounds or vehicle solutions, respectively.
All mini-osmotic pumps were incubated in sterile saline solution over-
night at 37 °C.
2.4. Paw pressure test
The nociceptive threshold in the rat was determined with an an-
algesiometer (Ugo Basile, Varese, Italy), according to the method de-
scribed by Leighton et al. (1988). Briefly, a constantly increasing
pressure was applied to a small area of the dorsal surface of the paw
using a blunt conical probe by a mechanical device. Mechanical pres-
sure was increased until vocalization or a withdrawal reflex occurred
while rats were lightly restrained. Vocalization or withdrawal reflex
thresholds were expressed in grams. Rats scoring below 35 g or over
75 g during the test before the surgical procedure for the catheter im-
plantations were rejected. For analgesia measures, mechanical pressure
application was stopped at 180 g. All experiments were performed by a
researcher blind to drug treatments.
2.5. Rota-rod test
The Rota-rod apparatus (Ugo Basile, Varese, Italy) consisted of a
base platform and a rotating rod with a diameter of 6 cm and a non-
slippery surface. The rod was placed at a height of 25 cm from the base.
The rod, 36 cm in length, was divided into 4 equal sections by 5 disks.
Thus, up to 4 rats were tested simultaneously on the apparatus, with a
rod-rotating speed of 10 r.p.m. The integrity of motor coordination was
assessed on the basis of the time the animals kept their balance on the
rotating rod up to a maximum of 120 s. The number of falls from the rod
was also measured. After a maximum of 6 falls, the test was suspended
and the time was recorded.
2.6. Immunofluorescence staining
After the disappearance of the antinociceptive effects (day 6 for
morphine-treated NOP(+/+); day 9 for morphine-treated NOP(-/-);
day 8 for morphine-treated NOP(+/+)) animals from each treatment
group were killed using a guillotine. The L4/L5 segments of the spinal
cord were exposed from the lumbar vertebral column via laminectomy
and identified by tracing the dorsal roots from their respective dorsal
root ganglia (DRG). As previously described by (Di Cesare Mannelli
et al., 2013, 2014; Tomassoni et al., 2013), formalin-fixed cryostat
sections (7 µm) were washed 3 × phosphate-buffered saline (PBS),
0.3% Triton X-100 for 5min and then were incubated, at room tem-
perature, for 1 h in blocking solution (PBS, 0.3% Triton X-100, 5% al-
bumin bovine serum; PBST). Slices were incubated overnight at 4 °C in
PBST containing rabbit primary antisera. The primary antibody used
was directed against ionized calcium binding adapter molecule 1 (Iba1;
rabbit, 1:1000; Wako, Richmond, VA, USA) for microglial staining or
against glial fibrillary acidic protein (GFAP; rabbit, 1:1000; DAKO,
Carpinteria, CA, USA) for astrocyte staining. The following day, slides
were washed 3 × PBS, 0.3% Triton X-100 for 5min and then sections
were incubated in goat anti-rabbit IgG secondary antibody labeled with
Alexa Fluor 568 (1:500; Invitrogen, Carlsbad, USA) and DAPI (4′, 6-
diamidin-2-fenilindolo; 1:2000; Life Technologies-Thermo scientific,
Rockford, IL, USA), a nuclei marker, in PBST at room temperature for
2 h, in the dark. After 3 × PBS 0.3% Triton X-100 wash for 10min,
slices were mounted using ProLong Gold (Life Technologies-Thermo
scientific, Rockford, IL, USA) as a mounting medium.
Negative control sections (no exposure to the primary antisera)
were processed concurrently with the other sections for all im-
munohistochemical studies, in order to exclude the presence of non-
specific immunofluorescent staining or cross-immunostaining. Images
were acquired by using an Olympus BX63 microscope equipped with an
Olympus XM10 camera and coupled to CellSense Dimension Software
(Olympus, Milan, Italy).
Quantitative analysis of GFAP and Iba1-positive cells was performed
by collecting three independent fields through a 20× 0.40NA objective
in the dorsal horn of each rat spinal cord. GFAP and Iba1-positive cells
were counted using the “cell counter” plugin of ImageJ (NIH, Bethesda,
Maryland, USA).
2.7. Statistical analysis
Behavioral measurements were performed on 8 rats for each treat-
ment carried out in 2 different experimental sets. Results were ex-
pressed as means± S.E.M. and the analysis of variance was performed
by two way ANOVA. A Bonferroni's significant difference procedure
was used as post-hoc comparison. P values of less than 0.05 or 0.01
were considered significant. Data were analyzed using the “Origin 9”
software (OriginLab, Northampton, USA).
3. Results
We compared the analgesic effects of morphine (1 nmol/h and
3 nmol/h) induced by a continuous intrathecal (i.t.) infusion in NOP
(+/+) and NOP(-/-) rats. Control groups were treated with sterile
saline solution. To allow a constant delivery of the substance over days,
mini-osmotic pumps connected to catheters were used. Pain threshold
was evaluated every day by Paw pressure test, beginning 24 h after
pump implant (Fig. 1A and B). Animals treated with vehicle displayed a
stable pain threshold over the time course of the experiment (10 days).
No difference in the basal pain threshold between NOP(+/+) and NOP
(-/-) rats was highlighted.
On day 1, morphine elicited a higher antinociceptive effect in NOP
(+/+) animals in comparison to the same dose infused in NOP(-/-)
rats. A superior effect in NOP(+/+) rats was maintained for 2 and 4
days depending on the treatment with 1 or 3 nmol/h, respectively. In
NOP(+/+) rats morphine effectiveness rapidly decreased (dose-de-
pendently) losing significance on day 5 (Fig. 1A and B). In NOP(-/-)
animals, the antinociceptive effect of morphine, even lower, was more
stable and longer lasting for both dosages used (1 and 3 nmol/h). Ef-
ficacy was lost on day 9 (Fig. 1A and B).
Results obtained by the continuous intrathecal infusion of the en-
dogenous peptide N/OFQ (1 and 3 nmol/h) in NOP(+/+) rats are
shown in Fig. 2. N/OFQ efficacy was slightly lower than morphine on
day 1 but the decrease in the following days was lesser drastic. More-
over, the antinociceptive effect was maintained till day 7. As previously
Fig. 2. Effect induced by continuous intrathecal infusion of N/OFQ in NOP (+/+) rats.
The compound was dissolved in sterile saline solution and administered in two different
groups of animals at the dosages of 1 and 3 nmol/h with osmotic pumps until day 8.
Vehicle NOP (+/+) group was infused with sterile saline solution. The nociceptive
threshold was evaluated by Paw pressure test, starting the 1st day of treatment. Each
value represents the mean of 8 rats performed in 2 different experimental sets. Data are
shown as mean±S.E.M; ^P< 0.05 and ^^P<0.01 vs vehicle NOP (+/+) infused rats.
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reported, N/OFQ does not induce analgesia in NOP(-/-) animals
(Micheli et al., 2015a).
After the disappearance of the antinociceptive effects (day 6 for
morphine-treated NOP(+/+) at the dose of 3 nmol/h; day 9 for
morphine-treated NOP(-/-) at both dosages (1 and 3 nmol/h); day 8 for
nociceptin/OFQ-treated NOP(+/+)) animals from each treatment
group were killed for spinal cord collection. The dorsal horn were
collected and glial cells analyzed by immunohistochemistry at the
Fig. 3. Iba1-positive cell density in the dorsal horn of the spinal cord of morphine NOP(+/+) and NOP(-/-) tolerant rats. a) Morphine 3 nmol/h was continuously intrathecal infused in
NOP(+/+) rats until the onset of tolerance and immunohistochemical analysis was performed on day 6. Representative images of merged Iba1-labeled microglia cells (red), plus DAPI-
labeled cell nuclei (blue), scale bar: 50 µm. b) Morphine 1 nmol/h and 3 nmol/h was continuously intrathecal infused in NOP(-/-) rats until the onset of tolerance and im-
munohistochemical analysis was performed on day 9. Representative images of merged Iba1-labeled microglia cells (red), plus DAPI-labeled cell nuclei (blue), scale bar: 50 µm. Each
value represents the mean of 4 rats performed in 2 different experimental sets. Data are shown as mean± S.E.M; ^^P< 0.01 vs vehicle NOP(+/+) infused rats. *P<0.05 and **P< 0.01
vs vehicle NOP(-/-) infused rats. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article).
L. Micheli et al. European Journal of Pharmacology 823 (2018) 79–86
82
lumbar level. In wild type animals, morphine, infused at the dose of
3 nmol/h, increased the number of both Iba1- and GFAP-positive cells
in comparison to control (Figs. 3A and 4A). Differently, the microglial
component only was increased by morphine (1 and 3 nmol/h) in NOP
(-/-) rats whereas astrocytes were unmodified by treatment (Figs. 3B
and 4B).
In Fig. 5, the effect of N/OFQ on glial cells is shown. The intrathecal
infusion of N/OFQ (1 nmol/h and 3 nmol/h) did not alter the number of
Fig. 4. GFAP-positive cell density in the dorsal horn of the spinal cord of morphine NOP(+/+) and NOP(-/-) tolerant rats. a) Morphine 3 nmol/h was continuously intrathecal infused in
NOP(+/+) rats until the onset of tolerance and immunohistochemical analysis was performed on day 6. Representative images of merged GFAP-labeled astrocytes cells (red), plus DAPI-
labeled cell nuclei (blue), scale bar: 50 µm. b) Morphine 1 nmol/h and 3 nmol/h was continuously intrathecal infused in NOP(-/-) rats until the onset of tolerance and im-
munohistochemical analysis was performed on day 9. Representative images of merged GFAP-labeled astrocytes cells (red), plus DAPI-labeled cell nuclei (blue), scale bar: 50 µm. Each
value represents the mean of 4 rats performed in 2 different experimental sets. Data are shown as mean±S.E.M; ^^P<0.01 vs vehicle NOP(+/+) infused rats. (For interpretation of the
references to color in this figure legend, the reader is referred to the web version of this article).
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Fig. 5. Iba1-positive cell density and GFAP-positive cell density in the dorsal horn of the spinal cord of N/OFQ NOP(+/+) tolerant rats. a) N/OFQ 1 nmol/h and 3 nmol/h was
continuously intrathecal infused in NOP(+/+) rats until the onset of tolerance and immunoistochemical analysis were performed on day 8. Representative images of merged Iba1-
labeled microglia cells (red), plus DAPI-labeled cell nuclei (blue), scale bar: 50 µm. b) N/OFQ 1 nmol/h and 3 nmol/h was continuously intrathecal infused in NOP(+/+) rats until the
onset of tolerance and immunoistochemical analysis were performed on day 4. Representative images of merged GFAP-labeled astrocytes cells (red), plus DAPI-labeled cell nuclei (blue),
scale bar: 50 µm. Each value represents the mean of 8 rats performed in 2 different experimental sets. Data are shown as mean±S.E.M; ^P<0.05 vs vehicle NOP(+/+) infused rats. (For
interpretation of the references to color in this figure legend, the reader is referred to the web version of this article).
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Iba-1 positive cells (Fig. 5B). On the contrary, the density of GFAP-
positive cells was significantly increased (Fig. 5B).
4. Discussion
Results showed that genetic deletion of NOP receptor is associated
with reduction in the analgesic effect and tolerance development of
morphine. Knocking out the NOP receptor, morphine is less efficient in
increasing the pain threshold but the effect is longer lasting in com-
parison with wild type animals. Moreover, immunohistochemistry re-
vealed that lack of NOP receptor is also associated with reduced acti-
vation of GFAP-positive cells occurring in morphine tolerant rats
indicating a potential role of NOP/OFQ system in regulation of toler-
ance through modulation of astrocytes-related mechanisms. This hy-
pothesis if further supported by results in wild type rats in which N/
OFQ infusion was associated with activation of astrocytes.
The lower analgesic efficacy of morphine in NOP(-/-) rats agree
with our previous evidence after an acute intrathecal injections in rats
(Micheli et al., 2015a). Conversely, other authors reported similar an-
algesic effects of morphine in NOP(+/+) and NOP(-/-) in mice
(Mamiya et al., 2001; Ueda et al., 1997) suggesting a different role of
N/OFQergic signaling in rats and mice. On the other hand, a partial loss
of tolerance liability to morphine analgesia was observed also in mice
lacking the NOP receptor gene (Ueda et al., 1997).
The development of morphine tolerance and dependence is also
associated with changes of the NOP receptor system. For instance, in
wild type mice, chronic administration of morphine induced an in-
crease of NOP gene expression in the spinal cord while the adminis-
tration of J-113397, a non-peptide N/OFQ antagonist (Bigoni et al.,
2000; Ozaki et al., 2000), prevented the development of morphine
tolerance (Caputi et al., 2014; Chung et al., 2006; Ueda et al., 2000).
Accordingly, the concentration of endogenous N/OFQ increased in the
rat ventricular cerebrospinal fluid, in periaqueductal gray and amyg-
dala in a time-dependent manner during the development of morphine
tolerance (Yuan et al., 1999).
During the development of morphine tolerance similar increases
were observed also for cholecystokinin (Becker et al., 2000; Lucas et al.,
1999) and neuropeptide FF (Malin et al., 1990), both of which have
been shown to contrast the analgesics effects of opioid in the central
nervous system. Hence, engagement of antiopioid peptide systems may
represent a key mechanism responsible for the development of toler-
ance to the analgesic effects of morphine (Harrison et al., 1998).
The demonstration that N/OFQ blocks opioid receptor-mediated
stress-induced antinociception (Mogil et al., 1996) and also decreases
the antinociceptive effect of morphine and other opioid receptor ago-
nists (Lutfy et al., 2001; Mogil et al., 1996; Morgan et al., 1997; Tian
et al., 1997) has led to the suggestion that N/OFQ may act as an anti-
opioid peptide in the brain (Mogil et al., 1996).
Among several mechanisms proposed to explain morphine toler-
ance, the activation of glial cells assumes a main role (Cui et al., 2008;
Eidson and Murphy, 2013; Ferrini et al., 2013; Song and Zhao, 2001).
To the best of our knowledge, there are no findings regarding the re-
lationship between glial cells and N/OFQ in the onset of morphine
tolerance.
In the present study we reported the glial response in the dorsal
horn of the spinal cord in NOP(+/+) and NOP(-/-) rats tolerant to
morphine. We performed the same analysis in NOP(+/+) rats tolerant
to N/OFQ. Wild type animals, tolerant to morphine after the intrathecal
continuous infusion of the alkaloid at the dose of 3 nmol/h, showed
glial activation characterized by an increase in cell density without
morphological alterations of both microglia and astrocytes. This results
are in accord with previous evidence (Di Cesare Mannelli et al., 2015).
On the contrary, in wild type rats tolerant to N/OFQ the number of
astrocyte cells is statistically increased whereas microglia density is not
altered. Nevertheless, when the NOP receptor is deleted morphine
treatment selectively activates microglia but not astrocytes. A NOP-
mediated morphine-induced astrocyte activation may be hypothesize.
On the other hand, fluorocitrate, a nonselective metabolic inhibitor of
astrocytes, partially reversed the development of morphine tolerance in
rats (Song and Zhao, 2001). Moreover, astrocytes express NOP receptor
and cytokine production by astrocytes can be inhibited by N/OFQ, an
effect which represents one mechanism by which N/OFQ may reduce
pain sensitivity (Fu et al., 2007). Furthermore, N/OFQ mRNA is in-
creased in astrocytes treated with morphine (Takayama and Ueda,
2005), further, various proinflammatory cytokines as those increased
during morphine treatment (eg., tumor necrosis factor and interleukin-
1) can enhance astrocyte concentrations of immunoreactive N/OFQ and
N/OFQ mRNA (Buzas et al., 2002; Mallimo and Kusnecov, 2013). In
this view, our data suggest that lacking NOP receptor the ancillary role
of N/OFQ in morphine antinociception is lost but losing the NOP-de-
pendent astrocyte signal tolerance development may be delayed. The
topic deserves further studies to clarify the role of N/OFQ signaling in
astrocyte and to attempt a NOP modulation for enhancing morphine
antinociceptive activity. In particular, an in vivo study with the con-
tinuous i.t. infusion of morphine and a NOP receptor antagonist will be
performed to highlight the link between the onset of morphine toler-
ance and the NOP system.
5. Conclusion
In conclusion the antinociceptive effect of morphine seems to be
partially dependent from the NOP system since rats lacking NOP re-
ceptor are less sensitive to the analgesic effect of this opioid agonist.
Interestingly, these results revealed also that receptor deletion con-
tributes to delay the development of morphine tolerance possibly
through mechanisms associated with astrocytes activation.
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